First Trimester Metformin in Polycystic Ovary Syndrome Patients with History of Recurrent Early Pregnancy Loss: Randomized Controlled Trial

Farid Ibrahim Hassan  
*Department of Obstetrics and Gynecology, Faculty of Medicine for boys, Al-Azhar University, Cairo, Egypt.*

Muhamed Ahmed Abdelmoaty  
*Department of Obstetrics and Gynecology, Faculty of Medicine for boys, Al-Azhar University, Cairo, Egypt.*

Ahmed Hamdy Muhammed Saad  
*Department of Obstetrics and Gynecology, Faculty of Medicine for boys, Al-Azhar University, Cairo, Egypt.*,  
ahmedobg2019@gmail.com

Follow this and additional works at: [https://aimj.researchcommons.org/journal](https://aimj.researchcommons.org/journal)

Part of the Medical Sciences Commons, Obstetrics and Gynecology Commons, and the Surgery Commons

**How to Cite This Article**  
Hassan, Farid Ibrahim; Abdelmoaty, Muhamed Ahmed; and Saad, Ahmed Hamdy Muhammed (2023) "First Trimester Metformin in Polycystic Ovary Syndrome Patients with History of Recurrent Early Pregnancy Loss: Randomized Controlled Trial," *Al-Azhar International Medical Journal*: Vol. 4: Iss. 10, Article 37.  
DOI: [https://doi.org/10.58675/2682-339X.1975](https://doi.org/10.58675/2682-339X.1975)

This Original Article is brought to you for free and open access by Al-Azhar International Medical Journal. It has been accepted for inclusion in Al-Azhar International Medical Journal by an authorized editor of Al-Azhar International Medical Journal. For more information, please contact dryasserhelmy@gmail.com.
ORIGINAL ARTICLE

First-trimester Metformin in Polycystic Ovary Syndrome Patients with History of Recurrent Early Pregnancy Loss: Randomized Controlled Trial

Ahmed Hamdy Mohamed Saad*, Muhamed Ahmed Abdelmoaty, Farid Ibrahim Hassan

Department of Obstetrics and Gynecology, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt

Abstract

Background: Women with polycystic ovarian syndrome (PCOS) who take metformin throughout their pregnancies have lower rates of miscarriage, labour, and foetal development restriction. Positive benefits of metformin on insulin sensitivity, plasma glucose concentration, and lipid profile have been shown in patients with polycystic ovary syndrome.

Aim and objectives: To the disparity in the occurrence of miscarriage between two patient cohorts who will get or not receive Metformin in the first trimester, to determine the efficacy of Metformin in preventing early pregnancy loss in pregnant patients with PCOs.

Subjects and methods: This was a randomised controlled trial that was conducted on 100 recently pregnant PCO patients at the Department of Obstetrics and Gynecology, Faculty of Medicine, Al-Azhar University, from January 2022 to November 2022.

Result: Group A had a much lower EPL rate than Group B.

Conclusion: In conclusion, Pregnant women with polycystic ovary syndrome who took metformin consistently during the first trimester had significantly lower rates of miscarriage. Patients accepted it well and experienced little negative effects. However, more research is needed to determine its impact on subsequent pregnancy problems and foetal outcomes.

Keywords: Early pregnancy loss, Insulin resistance, Metformin, Polycystic ovary syndrome

1. Introduction

Deplying on the criterion used, 1–2% of reproductive-aged women experience recurrent miscarriage. Nevertheless, accurate estimates are difficult to establish due to limited data availability. Obesity, insulin resistance, and persistent inflammation have all been linked to polycystic ovarian syndrome (PCOS). Significant barriers to establishing a pregnancy in women with PCOS include poor endometrial receptivity and repeated implantation failure.

Females of childbearing age are disproportionately affected by polycystic ovary syndrome (PCOS), this population's most common endocrine disorder. Type 2 diabetes mellitus may be managed by the biguanide metformin. It's been prescribed more often than any other antihyperglycemic drug. Mechanism of action involves lowering glucose synthesis within the body, especially in the liver.

Metformin, one of several insulin-sensitizing medicines, has been proven to decrease testosterone levels, leading to normalised ovulation and decreased miscarriage. Previous studies have indicated metformin's positive effects, but it remains unclear if the drug can be safely used throughout pregnancy.

By restoring ovulation, correcting infertility, preventing pregnancy loss, and lowering pregnancy-induced problems, metformin can improve

*Corresponding author at: Department of Obstetrics and Gynecology, Faculty of Medicine for Boys, Al-Azhar University, Resident of Obstetrics and Gynecology, Cairo, Egypt.
E-mail address: ahmedobg2019@gmail.com (A.H.M. Saad).

https://doi.org/10.5867/2682-339X.1975
2682-339X © 2023 The author. Published by Al-Azhar University, Faculty of Medicine. This is an open access article under the CC BY-SA 4.0 license (https://creativecommons.org/licenses/by-sa/4.0/).
reproductive abnormalities amongst females afflicted with PCOS. It was reported that continuing metformin during pregnancy is healthy and decreases first-trimester miscarriage from 64% to 5% without teratogenicity. Metformin usage may decrease the risk for early pregnancy loss by decreasing estrogen concentration and improving insulin sensitivity.

2. The study's overarching objective

To Determine Whether Metformin Has Any Effect on Reducing Pregnancy loss in pregnant PCO patients via a contrast of two patient cohorts who will or will not get it in the first trimester.

3. Patients and methods

This research was a randomized controlled study and included 100 pregnant women who were already diagnosed to have polycystic ovary syndrome and complained of recurrent early pregnancy loss. The participants were categorized in half, the first group (A) included 50 women who were on metformin treatment in a daily dose of 1000 mg, and treatment continued till 12 weeks of gestation, and women in the second group (B) 50 women serve as a control group. Women were selected from those who attended the outpatient clinic or inpatient ward of the Department of Obstetrics and Gynecology, at Al-Hussein university Hospital. From January 2022 to November 2022.

3.1. Inclusion criteria

Maternal age of 25–30, Patients who have had recurrent early pregnancy loss which is defined as loss of two or more consecutive pregnancies, Women with polycystic ovary syndrome who become pregnant, Diagnosis of PCOS before pregnancy and treatment with metformin based on Rotterdam criteria with at least two of the following three criteria will be fulfilled, Recently positive pregnancy test (Pregnancy is verified by a transvaginal ultrasound scan and a serum beta human chorionic gonadotropin level of 50 IU/l. Pregnancy occurred while on metformin therapy in group (A).

3.2. Exclusion criteria

Other type of abnormal pregnancy. (Blighted ovum, Ectopic pregnancy, vesicular mole), Other medical disorders like D.M, thyroid, Heart disease, systemic lupus erythematosus, rheumatoid arthritis, amyloidosis, atherosclerosis and antiphospholipid syndrome, Any uterine anomaly as excluded by transvaginal ultrasound scanning (unicornuate or bicornuate, submucous fibroid), Pregnant women after IVF, Uses of anticoagulant drugs. Not only do aberrant parental blood karyotypes increase the likelihood of a miscarriage, but so do other risk factors.

3.3. A standard set of tests was administered to every patient

Detailed history: including personal history and past history, obstetric history, history of last menstrual period (LMP), medical and surgical history, and previous history of miscarriage. Clinical examination: including (Maternal Body Maa Index (BMI) was calculated and Hyperandrogenism signs).

Routine investigation in the first trimester: Complete blood count (CBC, ABO and Rh typing).

Randomization and allocation: 100 Patients who met the needs were randomly divided into two categories using a computer-generated random sequence list (1:1). After that, we split everyone up into two groups: Group A (Metformin group): It contains 50 pcos women who became pregnant while on metformin (Cedophage ® 500 mg, CID pharma, Egypt) in a daily dose 1000 mg per day during the first trimester together with folic acid. Group B (Placebo group): it contains 50 pcos women who became pregnant and receive only folic acid.

Follow-up: Follow-up of both groups was carried out at 8th and 12th week gestation and thereafter routine ANC visits until delivery.

4. Results

Table 1.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Group A (n = 50)</th>
<th>Group B (n = 50)</th>
<th>t</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) Mean ± SD</td>
<td>28.52 ± 3.6</td>
<td>29.88 ± 5.35</td>
<td>1.49</td>
<td>0.139</td>
</tr>
<tr>
<td>Parity Mean ± SD</td>
<td>2.08 ± 0.976</td>
<td>2.17 ± 1.03</td>
<td>MU 249</td>
<td>0.622</td>
</tr>
<tr>
<td>BMI (kg/m²) Mean ± SD</td>
<td>27.03 ± 2.68</td>
<td>26.45 ± 2.29</td>
<td>0.543</td>
<td>0.592</td>
</tr>
</tbody>
</table>

Based on the data in the table, we can conclude that there is no statistically significant difference in age parity or body mass index between the groups (Table 2, Fig. 1).
The table above demonstrate that the EPL rate was significantly lower in group A compared to group B (Table 3).

This table shows that gestational diabetes, gestational hypertension, and preeclampsia incidences were lower in group A compared to group B, but statistically significant was found only in gestational diabetes (Table 4, Fig. 2).

This table shows that neonatal outcomes Group A had lower levels, on average, than Group B, but the difference was not statistically significant (Fig. 3 Table 5).

This table shows that the most common side effects were nausea & vomiting (40%) followed by heartburn (34%).

5. Discussion

Polycystic ovarian syndrome is the leading reason for female infertility in the United States, affecting 5-10 percentage of reproductive-age women. Patients who suffer from polycystic ovary syndrome have a higher chance of miscarriage following both natural and medically-assisted conception. Women with polycystic ovaries or polycystic ovarian syndrome, the risk of miscarriage in the first trimester was three times higher, defined as miscarriage during the first trimester, compared to the rate of 10-15% observed in retrospective studies for normal women.7

Type 2 diabetes mellitus can be treated with the biguanide metformin. It's been prescribed more often than any other antihyperglycemic drug. The reduction of liver glucose synthesis is crucial to its mechanism of action. Women of childbearing age who have polycystic ovary syndrome and have not

Table 2. Primary outcome distribution between the two groups.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Group A (n = 50)</th>
<th>Group B (n = 50)</th>
<th>(\chi^2)</th>
<th>(P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPL</td>
<td>5 (10%)</td>
<td>13 (26%)</td>
<td>4.34</td>
<td>0.037</td>
</tr>
</tbody>
</table>

Fig. 1. Rate of early pregnancy loss between the two groups.

Table 3. Secondary outcome distribution between the two groups.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Group A (n = 50)</th>
<th>Group B (n = 50)</th>
<th>(\chi^2)</th>
<th>(P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational diabetes</td>
<td>6 (12%)</td>
<td>14 (28%)</td>
<td>4</td>
<td>0.046</td>
</tr>
<tr>
<td>Gestational Hypertension</td>
<td>5 (10%)</td>
<td>8 (16%)</td>
<td>0.796</td>
<td>0.372</td>
</tr>
<tr>
<td>Preeclampsia</td>
<td>2 (4%)</td>
<td>5 (10%)</td>
<td>1.38</td>
<td>0.240</td>
</tr>
</tbody>
</table>

Table 4. Neonatal outcome distribution between the two groups.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Group A (n = 50)</th>
<th>Group B (n = 50)</th>
<th>(\chi^2)</th>
<th>(P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prematurity</td>
<td>3 (6%)</td>
<td>4 (8%)</td>
<td>0.154</td>
<td>0.695</td>
</tr>
<tr>
<td>Macrosomia</td>
<td>2 (4%)</td>
<td>3 (6%)</td>
<td>0.211</td>
<td>0.646</td>
</tr>
<tr>
<td>IUGR</td>
<td>3 (6%)</td>
<td>5 (10%)</td>
<td>0.544</td>
<td>0.461</td>
</tr>
<tr>
<td>APGAR at 5 min &lt; 7</td>
<td>4 (8%)</td>
<td>5 (10%)</td>
<td>0.122</td>
<td>0.727</td>
</tr>
<tr>
<td>Anomalies</td>
<td>0</td>
<td>1 (2%)</td>
<td>1.01</td>
<td>0.317</td>
</tr>
</tbody>
</table>
responded to ovulation-inducing medications like clomiphene may benefit greatly from taking metformin. By statistical analysis, we determined that neither group differed significantly from the other in terms of age, parity, or body mass index (BMI), and that the mean SD for group A was 28.52 ± 3.6 years and for group B it was 29.88 ± 5.35 years. In line with our findings, according to the research by Jakubowicz et al., 48 of the 65 women who took metformin had already given birth at least once, whereas 17 were unable to have children. Age, parity, and BMI were not statistically different across groups, and none of the women had taken metformin during their prior pregnancies. Liu et al. found that of the 65 women who used metformin, 48 had a history of at least one past pregnancy and 17 were nulliparous. Metformin was not used by any of the women in any of their prior pregnancies. Sixty-two live births and fifty-three miscarriages were recorded among the seventy-five pregnancies had by the 48 Metformin-treated females who had previously given birth. Twenty-one of the thirty-one women in the groups of the control

In line with our findings, according to the research by Jakubowicz et al., 948 of the 65 women who took metformin had already given birth at least once, whereas 17 were unable to have children. Age, parity, and BMI were not statistically different across groups, and none of the women had taken metformin during their prior pregnancies. Liu et al.10 found that of the 65 women who used metformin, 48 had a history of at least one past pregnancy and 17 were nulliparous. Metformin was not used by any of the women in any of their prior pregnancies. Sixty-two live births and fifty-three miscarriages were recorded among the seventy-five pregnancies had by the 48 Metformin-treated females who had previously given birth. Twenty-one of the thirty-one women in the groups of the control

Table 5. Metformin side effects distribution among Metformin group.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Group A (n = 50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea &amp; vomiting</td>
<td>20 (40%)</td>
</tr>
<tr>
<td>Gastric irritation</td>
<td>17 (34%)</td>
</tr>
<tr>
<td>(heartburn, discomfort, …)</td>
<td></td>
</tr>
<tr>
<td>Abdominal distention</td>
<td>8 (16%)</td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td>2 (4%)</td>
</tr>
</tbody>
</table>
condition had a record of at least one previous pregnancy, whereas ten were nulliparous. There were a total of 24 pregnancies among the 21 women in the control group, 11 of which led to successful pregnancies and healthy babies, for a miscarriage rate of 54.2%. Within that study, age had also been supplied, with a mean SD of 29.5 ± 3.7 years for group A and 30 ± 1.9 years for group B.

Patient PCOS is associated with a higher risk of having an unfavourable pregnancy outcome, however, there is now incongruity in the research on the mechanisms that contribute to this. Age, weight, and use of IVF are all examples of potential dangers. The clinical manifestations of polycystic ovary syndrome (PCOS) in patients are quite variable.

In the study on our hands, we found that the incidence of EPL was 5 (10%) in group A, and was 13 (26%) in the control group.

The percentage of EPLs was much lower in Group A than in Group B.

Researchers Hussein et al. showed that giving Metformin to pregnant women in the first trimester significantly lowered the miscarriage rate. Pregnancy losses as a percentage of the total that started using Metformin dropped to 10.8%, but it was 42.2% in the group that stopped taking Metformin (p 0.05). Significantly more people in the Metformin group experienced adverse effects like nausea, vomiting, gastric irritation, and flatulence than in the other group (15.1% vs. 38.1%), but no serious side effects were reported (i.e.: lactic acidosis).

Sohrabvand et al. conducted a similar trial with three groups totaling 75 pregnant women with PCOS. When pregnancy was detected, Group A patients immediately stopped using metformin (500 mg TDS) (5–6 weeks gestation) Metformin was given to Group B till 8 weeks gestation and Group C until 12 weeks. Miscarriage rates decreased from 40% in Group B to 8% in Group C, and from 32% to 4% in Group C, indicating a statistically significant difference between prior and current pregnancies. Although Group A had a far lower miscarriage rate (from 20% to 4%), The size of the sample was insufficient to draw any firm conclusions.

Although all three conditions were shown to be less common in group A than in group B, the difference was only statistically significant for gestational diabetes.

Women in Group A had a somewhat lower risk of developing gestational hypertension than women in Group B, according to the results of this study (p value: 0.372). Abd El Hameed et al. found a similar result, albeit without statistical significance, reporting that metformin users had a decreased rate of developing gestational hypertension than those who did not take the drug. Preeclampsia occurred in fewer women in the metformin group than in the placebo group (3.0% vs. 11.3%; odds ratio, 0.24; 95% confidence range, 0.10 to 0.61; \( P = 0.001 \)).

Conclusions of the incidence of GDM was nearly twice as high in the group B of women who stopped taking metformin compared to the group A of women who maintained metformin medication, 14 (28%) versus 6 (12%) with a \( P \) value of 0.046.

Ainuddin et al. revealed that while just 1 patient in the metformin group (4.6%) acquired GDM, 9 patients in the no metformin group (40.9%, 0.004) did. Those who did not take metformin were found to have a fourfold higher risk of developing GDM compared to those who did.

While it’s true that women with PCOS are at a higher risk for developing GDM than healthy women, metformin was linked to a reduction in the incidence of GDM in women with PCOS that was roughly 10 times greater than that seen in women without PCOS.

Metformin has been shown in numerous trials to decrease the occurrence of gestational diabetes, preeclampsia, and foetal macrosomia.

According to Khattab et al., Metformin’s effectiveness in reducing the occurrence of type 2 diabetes and preeclampsia in women with PCOS is encouraging.

Metformin use during pregnancy was linked to and perhaps responsible for a decline that is nine times greater (30–3.44%) in GDM in women with PCOS.

In keeping with previous studies, Zeng et al. found a precipitous drop in the frequency of negative pregnancy complications such gestational diabetes and hypertension.

According to the results of this study, newborn outcomes were reported to be poorer in group A compared to group B, despite the fact that no statistically significant difference existed between the two groups.

The risk of preterm birth, macrosomia, IUGR, foetal hypoxia (Apgar score 7), and congenital anomalies was slightly reduced in women who continued metformin therapy throughout the first trimester of pregnancy compared to women who discontinued taking metformin during the first trimester.

The incidence of neonatal growth deficits, congenital abnormalities, and admission to the neonatal critical care unit compared to the control group were lower in the metformin group, or lower in the metformin-treated group, according to a study by Diamanti-Kandarakis et al. Gilbert et al. agreed that there was no proof that using metformin in the first trimester increased the
incidence of serious abnormalities. Metformin is beneficial for both the mother and the developing child when taken before pregnancy in women with PCOS and continued until term. This includes a decrease in maternal complications such as type 2 diabetes, hypertension, and premature labour (lowering rates of miscarriage and foetal development restriction). Exposure to metformin during pregnancy has lasting consequences for the child’s brain development, which remain mostly unknown. At 9 years, there appeared to be no significant difference between the metformin and insulin groups with regard to body fat, visceral adipose tissue, or liver fat, suggesting that the MiG TOFU had no effect.

Body-mass-index increases in metformin-exposed kids may, on the other hand, be indicative of an elevated risk of childhood obesity. However, the results are not easily interpreted due to the low follow-up rate. Long-term investigations that begin with the children of women participating in the obesity trials will help shed light on this question.21

The metformin group had 62 live births, as shown by Daniela et al. There were 53 full-term births and 8 preterm births (37 weeks). All of the newborns were healthy and of suitable size for their gestational ages. Achondroplasia was the only foetal anomaly seen in a single full-term delivery. Eighteen live births occurred among the non-experimental group. Twelve were full-term births, and six were premature. In the group given the placebo, there were no birth defects.

Based on the results of this study, dizziness and headache were the least prevalent adverse effects, with nausea and vomiting (40%) and heartburn (34%). According to Lord et al., the results were consistent across studies. Most participants dropped out of one study due to stomach pain. No severe adverse events were reported during the trials.

5.1. Conclusion

Conclusion Continued use of metformin in the first trimester of pregnancy by women with polycystic ovary syndrome was linked with a significantly lower incidence of early pregnancy loss. Patients reported minimal, manageable adverse effects. In order to fully understand its impact on future pregnancy problems and foetal outcomes, however, larger research are necessary Fig. 2.

Authorship

I1 authors have a substantial contribution to the article.

Disclosure

The authors have no financial interest to declare in relation to the content of this article.

Conflicts of interest

The authors declared that there were NO conflicts of Interest.

References


